Cancer vaccine strategies get bigger and better

Tanja D. De Gruijl*, David T. Curiel

*Corresponding author for this work

Research output: Contribution to journalShort surveyAcademicpeer-review

Abstract

Many anti-tumor vaccines have failed in recent clinical trials because they included the wrong patients and the wrong immune adjuvants - and little was learned because the anti-tumor immune response was not carefully monitored. A new tumor vaccine for lymphoma sets the stage for how future trials should be carried out (pages 1171-1177).

Original languageEnglish
Pages (from-to)1124-1125
Number of pages2
JournalNature Medicine
Volume5
Issue number10
DOIs
Publication statusPublished - 1 Oct 1999

Cite this